Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.51 |
| ▸ | MAPT | P10636 | 5/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | WNT3A | P56704 | 1/20 | 0.47 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.47 |
| ▸ | GLA | P06280 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 4/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 4/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | DRD2 | P14416 | 2/20 | 0.43 |
| ▸ | DRD3 | P35462 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | PLD2 | O14939 | 1/20 | 0.42 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3838939 | 1.00 | KDM4E (0.51) | KDM4EALDH1A1MAPTSMN1; SMN2WNT3A | |
| SCHEMBL5409708 | 0.78 | KDM4E (0.51) | KDM4EALDH1A1MAPTSMN1; SMN2GLA | |
| SCHEMBL5409697 | 0.78 | KDM4E (0.51) | KDM4EALDH1A1MAPTSMN1; SMN2GLA | |
| SCHEMBL6398124 | 0.77 | BCHE (0.58) | MAPTMEN1KMT2ADRD2DRD3 | |
| SCHEMBL6398120 | 0.77 | BCHE (0.58) | MAPTMEN1KMT2ADRD2DRD3 | |
| SCHEMBL5703482 | 0.76 | CCR3 (0.51) | KDM4EALDH1A1SMN1; SMN2DRD2DRD3 | |
| SCHEMBL5703480 | 0.76 | CCR3 (0.51) | KDM4EALDH1A1SMN1; SMN2DRD2DRD3 | |
| SCHEMBL10712188 | 0.74 | WNT3A (0.69) | ALDH1A1MAPTSMN1; SMN2WNT3ATNKS2 | |
| Hydrochloric Acid SCHEMBL10711744 | 0.74 | WNT3A (0.68) | ALDH1A1MAPTSMN1; SMN2WNT3ATNKS2 | |
| SCHEMBL10712753 | 0.73 | WNT3A (0.67) | MAPTWNT3ATNKS2KMT2ADRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1303488-B1 | PIPERIDINE COMPOUNDS FOR USE AS CCR-3 INHIBITORS | NOVARTIS AG (CH) | 2009-11-04 | — | — | EP | disclosed |
| US-6670379-B2 | Inflammatory or allergic conditions, asthma, inhibition of eosinophil activation, conjunctivitis; (1-((R2-Amino-3-pyridin-3-yl-propyl)-piperidin-4-yl)-(4-fluoro-phenyl) -methanone | NOVARTIS AG (CH) | 2003-12-30 | — | — | US | disclosed |
| US-20030176460-A1 | Piperidine compounds for use as ccr-3 inhibitors | NOVARTIS AG (CH) | 2003-09-18 | — | — | US | disclosed |
| EP-1303488-A1 | PIPERIDINE COMPOUNDS FOR USE AS CCR-3 INHIBITORS | Novartis AG (CH) | 2003-04-23 | — | — | EP | disclosed |
| WO-2002004420-A1 | PIPERIDINE COUMPOUNDS FOR USE AS CCR-3 INHIBITORS | NOVARTIS AG (CH) | 2002-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176460-A1 | Piperidine compounds for use as ccr-3 inhibitors | CCR1, CCR3, CCR4 | KDM4E 3515/4885ALDH1A1 1340/4885MAPT 4276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.